Free shipping on all orders over $ 500

JPH203

Cat. No. M6255
JPH203 Structure
Synonym:

KYT-0353

Size Price Availability Quantity
10mg USD 157  USD157 In stock
50mg USD 457  USD457 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: JPH203 completely and slightly inhibits the L-Leucine uptake in YD-38 cells (IC50 value: 0.79 μM) and NHOKs (IC50 value: >100 μM), respectively. JPH203 inhibits HT-29 cell growth, generating an apparent IC50 of 4.1 μM, but the JPH203 IC50 concentration (0.06 μM) needed to inhibit the L-Leucine uptake does not inhibit HT-29 cell growth, which represents a 68-fold difference in susceptibility. JPH203 activates the mitochondria-dependent apoptotic signaling pathway by upregulating pro-apoptotic factors, such as Bad, Bax, and Bak, and the active form of caspase-9, and downregulating anti-apoptotic factors, such as Bcl-2 and Bcl-xL in Saos2 human osteosarcoma cells. JPH203 can distinguish relative abundance between LAT1 and LAT2. It has high selectivity for LAT1. JPH203 is metabolically stable in mouse, rat, dog, monkey and human liver microsomal incubations. JPH203 induces both G2/M and G0/G1 cell cycle arrest, as well as reduces the S phase accompanied by altered expression of the proteins in cell cycle progression: cyclin D1, CDK4, and CDK6.

In vivo: Daily intravenous administration of JPH203 (12.5 and 25 mg/kg) significantly inhibits tumor growth in KKU-213 cholangiocarcinoma cell xenografts in the nude mice model in a dose-dependent manner with no statistically significant change in the animal’s body weight and with no differences in the histology and appearance of the internal organs compared with the control group. Thus, JPH203 shows anti-tumor efficacy in nude mice bearing human CCA cell xenografts without general toxicity.

Product Citations
Protocol (for reference only)
Cell Experiment
Cell lines Saos2 human osteosarcoma cells
Preparation method Colony formation assays are performed by seeding 300 cells/well into 6 well plates. After 24 h of growth, the cells are treated with 100 µM JPH203 for 72 h. The JPH203 treatment is removed and fresh medium is added. The cells are incubated for 10 days. Thereafter, medium is removed and the cells are washed with phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde for 10 min at 4℃. Sequentially, the colonies are stained with 2% crystal violet for 10 min. Finally, colonies stained by crystal violet are washed with PBS and dried at room temperature, before imaged by a digital camera.
Concentrations 100 µM
Incubation time 72 hours
Animal Experiment
Animal models Sprague-Dawley rats
Formulation dissolved in DMSO and diluted in water
Dosages 0.9-1.0 mg/kg
Administration i.v.
Chemical Information
Molecular Weight 472.32
Formula C23H19Cl2N3O4
CAS Number 1037592-40-7
Solubility (25°C) 10 mM in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Yun DW, et al. J Pharmacol Sci. JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells.

[2] Toyoshima J, et al. J Pharm Sci. Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203.

Related Autophagy Products
P62-mediated mitophagy inducer

P62-mediated mitophagy inducer (PMI) is a P62-mediated mitophagy activator. P62-mediated mitophagy inducer activates mitochondrial autophagy without recruitment of Parkin or collapse of the mitochondrial membrane potential and remains active in cells lacking a fully functional PINK1/Parkin pathway.

FDW028

FDW028 is a potent and highly selective FUT8 inhibitor. FDW028 exhibits potent anti-tumor activity by defucosylation and impelling lysosomal degradation of B7-H3 through the CMA pathway.

Calmodulin-Dependent Protein Kinase II (290-309)

Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II.

Microcolin H

Microcolin H is a marine lipopeptide and phosphatidylinositol transfer protein ligand that targets PITPα/β.

Forigerimod

Forigerimod (IPP-201101) is a CD4 T-cell modulator.

  Catalog
Abmole Inhibitor Catalog




Keywords: JPH203, KYT-0353 supplier, Autophagy, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.